IL-17 Triggers Invasive and Migratory Properties in Human MSCs, while IFNy Favors their Immunosuppressive Capabilities: Implications for the “Licensing” Process

Mesenchymal stromal cells (MSCs) were first used as a source for cell therapy in 1995; however, despite their versatility and unambiguous demonstration of efficacy and safety in preclinical/phase I studies, the positive effect of MSCs in human phase III studies did not resemble the success obtained...

Descripción completa

Detalles Bibliográficos
Autores principales: Du-Rocher, Bárbara, Binato, Renata, de-Freitas-Junior, Julio Cesar Madureira, Corrêa, Stephany, Mencalha, André Luiz, Morgado-Díaz, José Andrés, Abdelhay, Eliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667142/
https://www.ncbi.nlm.nih.gov/pubmed/33067729
http://dx.doi.org/10.1007/s12015-020-10051-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667142/
https://www.ncbi.nlm.nih.gov/pubmed/33067729
http://dx.doi.org/10.1007/s12015-020-10051-4

Ejemplares similares